| scholarly article | Q13442814 |
| review article | Q7318358 |
| P953 | full work available at URL | http://www.bloodjournal.org/cgi/content/abstract/78/12/3114 |
| P698 | PubMed publication ID | 1742478 |
| P2093 | author name string | D. Collen | |
| H. R. Lijnen | |||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | fibrinolysis | Q1410794 |
| thrombolysis | Q1931577 | ||
| P304 | page(s) | 3114-3124 | |
| P577 | publication date | 1991-12-01 | |
| 1991-12-15 | |||
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Basic and clinical aspects of fibrinolysis and thrombolysis | |
| P478 | volume | 78 |
| Q36291166 | A Smoothened receptor agonist is neuroprotective and promotes regeneration after ischemic brain injury |
| Q41223914 | A high affinity interaction of plasminogen with fibrin is not essential for efficient activation by tissue-type plasminogen activator |
| Q59400009 | A local uPAR-plasmin-TGFβ1 positive feedback loop in a qualitative computational model of angiogenic sprouting explains the in vitro effect of fibrinogen variants |
| Q33858132 | A murine model of myocardial microvascular thrombosis |
| Q40492572 | Anticoagulation and thrombolysis in children. |
| Q36536357 | Binding of the COOH-terminal lysine residue of streptokinase to plasmin(ogen) kringles enhances formation of the streptokinase.plasmin(ogen) catalytic complexes |
| Q41864031 | Carboxypeptidases: new regulators of plasminogen activation in vivo? |
| Q24544290 | Cell-type specific DNA-protein interactions at the tissue-type plasminogen activator promoter in human endothelial and HeLa cells in vivo and in vitro |
| Q30826562 | Cerebral microvascular obstruction by fibrin is associated with upregulation of PAI-1 acutely after onset of focal embolic ischemia in rats |
| Q79127117 | Cerebral venous sinus thrombosis |
| Q39250578 | Characterization of plasminogen binding to NB4 promyelocytic cells using monoclonal antibodies against receptor-induced binding sites in cell-bound plasminogen |
| Q44518209 | Coronary capillary network remodeling and hypofibrinolysis in aged obese diabetic rats: implications for increased myocardial vulnerability to ischemia |
| Q37340572 | Cryptic peptides of the kringle domains preferentially bind to disease-associated prion protein. |
| Q73283603 | Current Clinical Experience with Staphylokinase in Arterial Thrombosis |
| Q48544196 | D-dimers increase in acute ischemic stroke patients with the large artery occlusion, but do not depend on the time of artery recanalization |
| Q36438240 | Decreased fibrinolytic activity in porcine-to-primate cardiac xenotransplantation |
| Q91909639 | Diffusion-Reaction Models of Genipin Incorporation into Fibrin Networks |
| Q40467552 | Drug interactions with thrombolytic agents. Current perspectives. |
| Q37074787 | Effect of Fagonia arabica on thrombin induced release of t-PA and complex of PAI-1 tPA in cultured HUVE cells |
| Q93092155 | Effects of Plasmin on von Willebrand Factor and Platelets: A Narrative Review |
| Q24630061 | Engineering of TEV protease variants by yeast ER sequestration screening (YESS) of combinatorial libraries |
| Q34324817 | Enhanced venous thrombus resolution in plasminogen activator inhibitor type-2 deficient mice |
| Q42134236 | Expression and activity of the urokinase plasminogen activator system in canine primary brain tumors |
| Q40894293 | Expression of recombinant staphylokinase, a fibrin-specific plasminogen activator of bacterial origin, in potato (Solanum tuberosum L.) plants |
| Q37627304 | Expression of uPA, tPA, and PAI-1 in Calcified Aortic Valves. |
| Q37355459 | Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator |
| Q35918056 | Fibrinolytic Activity of Blood and its Determinants in Healthy Medical Students |
| Q34027250 | Fibrinolytic function and coronary risk |
| Q50785406 | GluN2D subunit-containing NMDA receptors control tissue plasminogen activator-mediated spatial memory. |
| Q47113597 | Hemostasis in Overt and Subclinical Hyperthyroidism |
| Q26777261 | Impacts of tissue-type plasminogen activator (tPA) on neuronal survival |
| Q39776706 | Impaired arterial neointima formation in mice with disruption of the plasminogen gene |
| Q35788548 | Impaired fibrinolytic system in ApoE gene-deleted mice with hyperlipidemia augments deep vein thrombosis |
| Q31153639 | Lack of alpha 2-antiplasmin enhances ADP induced platelet micro-aggregation through the presence of excess active plasmin in mice |
| Q30458285 | Laser enhanced high-intensity focused ultrasound thrombolysis: an in vitro study |
| Q37415725 | Mice lacking the gene encoding tissue-type plasminogen activator show a selective interference with late-phase long-term potentiation in both Schaffer collateral and mossy fiber pathways |
| Q34013442 | Molecular basis of thrombolytic therapy |
| Q37523317 | Molecular contributions to neurovascular unit dysfunctions after brain injuries: lessons for target-specific drug development |
| Q40875276 | Monoclonal antibodies with equal specificity to D-dimer and high-molecular-weight fibrin degradation products |
| Q30833796 | Neuroserpin is expressed in the pituitary and adrenal glands and induces the extension of neurite-like processes in AtT-20 cells |
| Q33680725 | Ovulation efficiency is reduced in mice that lack plasminogen activator gene function: functional redundancy among physiological plasminogen activators |
| Q89180918 | PAI1 blocks NMDA receptor-mediated effects of tissue-type plasminogen activator on cell signaling and physiology |
| Q38704015 | Peptides with 6-Aminohexanoic Acid: Synthesis and Evaluation as Plasmin Inhibitors |
| Q24677226 | Plasma carboxypeptidases as regulators of the plasminogen system |
| Q34473656 | Plasma clot lysis time and its association with cardiovascular risk factors in black Africans |
| Q30392562 | Plasmin-loaded echogenic liposomes for ultrasound-mediated thrombolysis |
| Q33909797 | Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization |
| Q49762151 | Plasminogen activator inhibitor-1: a risk factor for deep vein thrombosis after total hip arthroplasty |
| Q79501751 | Plasminogen and angiostatin interact with heat shock proteins |
| Q33818848 | Plasminogen regulates cardiac repair after myocardial infarction through its noncanonical function in stem cell homing to the infarcted heart |
| Q37339330 | Plasminogen substrate recognition by the streptokinase-plasminogen catalytic complex is facilitated by Arg253, Lys256, and Lys257 in the streptokinase beta-domain and kringle 5 of the substrate. |
| Q57810625 | Plasminogen/thrombomodulin signaling enhances VEGF expression to promote cutaneous wound healing |
| Q35929823 | Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progression |
| Q42012645 | Preparation, Optimization and Activity Evaluation of PLGA/Streptokinase Nanoparticles Using Electrospray |
| Q39603986 | Profibrinolytic effect of Enzamin, an extract of metabolic products from Bacillus subtilis AK and Lactobacillus |
| Q33630907 | Proteolytic resistance conferred to fibrinogen by von Willebrand factor. |
| Q44546816 | Purification and characterization of a novel fibrinolytic protease from Fusarium sp. CPCC 480097. |
| Q36254926 | Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice |
| Q37387907 | Reduced transplant arteriosclerosis in plasminogen-deficient mice |
| Q38583085 | Role of mesenchymal stem cell-derived fibrinolytic factor in tissue regeneration and cancer progression |
| Q55427987 | Roles of plasminogen in the alterations in bone marrow hematopoietic stem cells during bone repair. |
| Q38868099 | Selective inhibition of GluN2D-containing N-methyl-D-aspartate receptors prevents tissue plasminogen activator-promoted neurotoxicity both in vitro and in vivo |
| Q92374167 | Site-specific PEGylation of micro-plasmin for improved thrombolytic therapy through engineering enhanced resistance against serpin mediated inhibition |
| Q64913297 | Standardization of Measurement of Components of the Fibrinolytic System - Introduction and Current Status. |
| Q46158053 | Stem cells downregulate the elevated levels of tissue plasminogen activator in rats after spinal cord injury |
| Q34163191 | Targeted thrombolysis strategies for neuroprotective effect |
| Q39370856 | Targeting Hypoxia Inducible Factors-1α As a Novel Therapy in Fibrosis |
| Q41136821 | Temperature-sensitive liposome-mediated delivery of thrombolytic agents |
| Q46907772 | Testosterone upregulation of tissue type plasminogen activator expression in Sertoli cells : tPA expression in Sertoli cells |
| Q38803641 | The evolution of recombinant thrombolytics: Current status and future directions |
| Q41195276 | The glycosylation of Bowes melanoma tissue plasminogen activator: lectin mapping, reaction with anti-L2/HNK-1 antibodies and the presence of sulphated/glucuronic acid containing glycans |
| Q43264477 | The interaction between components of the fibrinolytic system and GPIb/V/IX of platelets thrombus formation in mice |
| Q37817023 | The plasmin-antiplasmin system: structural and functional aspects |
| Q27003277 | The prothrombotic tendency in metabolic syndrome: focus on the potential mechanisms involved in impaired haemostasis and fibrinolytic balance |
| Q55314224 | Tissue plasminogen activator for thrombolytic therapy: expectation versus reality |
| Q33588521 | Tissue-type plasminogen activator is a homeostatic regulator of synaptic function in the central nervous system |
| Q33691725 | Tranexamic acid-induced ligneous conjunctivitis with renal failure showed reversible hypoplasminogenaemia |
| Q34167946 | Urokinase plasminogen activator impairs SNP and PGE2 cerebrovasodilation after brain injury through activation of LRP and ERK MAPK. |
| Q36293106 | Urokinase-type plasminogen activator: a new target for male contraception? |
| Q36469555 | tPA contributes to impaired NMDA cerebrovasodilation after traumatic brain injury through activation of JNK MAPK. |
| Q34570654 | tPA contributes to impairment of ATP and Ca sensitive K channel mediated cerebrovasodilation after hypoxia/ischemia through upregulation of ERK MAPK. |
| Q36948533 | uPA impairs cerebrovasodilation after hypoxia/ischemia through LRP and ERK MAPK |
| Q36512703 | uPA modulates the age-dependent effect of brain injury on cerebral hemodynamics through LRP and ERK MAPK. |
Search more.